GSK - Theravance: All-Round Failure March, 10 2022 07:33 AM GlaxoSmithKline PLC Theravance failed 3 trials last year. There was a major restructuring and change of focus. A small revenue stream from YUPELRI is its only positive, but that doesn't justify the valuation. For further details see: Theravance: All-Round Failure